We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dermira, Inc. (“Dermira” or the “Company”) (NASDAQ: DERM) to Eli Lilly and Company (“Lilly”) (NYSE: LLY). Under the terms of the agreement, Lilly will acquire Dermira for $18.75 per share in an all-cash transaction.
The Dermira merger investigation concerns whether the Board of Dermira breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction and whether Lilly is underpaying for Dermira shares, thus unlawfully harming Dermira shareholders.
To receive more information, please fill out the form.